Hyperuricemia and Left Ventricular Diastolic Function

NCT03495999 | Terminated

• 1 other identifier: 2-106-05-078
• Study Type: observational
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

Metabolic syndrome and hyperuricemia were both associated with inflammation, leading to diversities of cardiovascular disease such as left ventricular diastolic dysfunction, but the relationship among these entities remained unclear. The aim of the present study focuses on the association among hyperuricemia, diastolic dysfunction and inflammatory biomarkers in apparently healthy individuals with metabolic syndrome

Conditions

Hyperuricemia; Metabolic Syndrome; Left Ventricular Diastolic Dysfunction

Keywords

Hyperuricemia; Metabolic syndrome; Left ventricular diastolic dysfunction; Inflammation

Outcome Measures

Primary Outcomes (1)

• Left ventricle diastolic dysfunction with elevated left atrial pressure

  The contemporary definition of left ventricular diastolic dysfunction with elevated left atrial pressure is mainly \>50% positive of the following criteria: (1) average E/e' ≥14 (2) left atrial volume index \>34 ml/m2 (3) tricuspid regurgitation velocity \>2.8 m/s

  1 day

Secondary Outcomes (3)

• high-sensitivity C-reactive protein

  1 week

• high-sensitivity interleukin-6

  1 month

• tumor necrotizing factor alpha

  1 month

Study Arms (2)

Normouricemia

Serum uric of 7mg/dl or less in men or 6mg/dl or less in women

Diagnostic Test: hyperuricemia

Hyperuricemia

Serum uric of 7mg/dl or more in men or 6mg/dl or more in women

Diagnostic Test: hyperuricemia

Interventions

hyperuricemia DIAGNOSTIC_TEST

serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Hyperuricemia; Normouricemia

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Apparently healthy individuals with metabolic syndrome

You may qualify if:

• Age between 20 to 75 years
• Metabolic syndrome

You may not qualify if:

• Left ventricular ejection fraction \<40%
• Severe valvular heart disease
• Significant structure heart diseases such as hypertrophic, dilated, infiltrative or restrictive cardiomyopathy, or congenital heart disease
• Persistent or chronic atrial fibrillation
• Status post cardiac surgery, including coronary artery bypass surgery of valve intervention
• Status post intra-cardiac device implantation
• Chronic obstructive pulmonary disease
• Severe anemia
• An obvious systemic disease that interferes left ventricular diastolic dysfunction such as acute coronary syndrome

Sponsors & Collaborators

• National Defense Medical Center, Taiwan: lead

Study Sites (1)

Tri-service General Hospital, songshan branch

Taipei, Songshan Dist., 105, Taiwan

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma

MeSH Terms

Conditions

Hyperuricemia; Metabolic Syndrome; Ventricular Dysfunction, Left; Inflammation

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Ventricular Dysfunction; Heart Diseases; Cardiovascular Diseases

Study Officials

• Cheng-Wei Liu, M.D.

  Tri-service General hospital, Songshan branch, National defense medical center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Cardiologist

Study Record Dates

• First Submitted: April 3, 2018
• First Posted: April 12, 2018
• Study Start: August 1, 2017
• Primary Completion: December 15, 2017
• Study Completion: April 3, 2018
• Last Updated: April 12, 2018

Record last verified: 2018-04

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)